In summary, the existence of multiple epigenetic mechanisms controlling the NRF2/KEAP1 pathway opens new exciting opportunities for therapeutic manipulations of NRF2 oncogenic signaling not related to its direct pharmacologic inhibition, although additional research is needed to better clarify potential risks and benefits of this approach in cancer patients. This evidence concerns the gene NFE2L2 and cancer.